Study | Country | N pts | Age (years) | p-STAT3+ (%) | STAT3+ (%) | Pathological type (cancer/ borderline/ benign/ normal) | Histological type (S/C/E/M) | FIGO stage (I-II/III-IV) | Tumour grade (G1 + G2/ G3) | LN (yes/no) | Anti- body | Scoring method | Cut-off value | Follow-up (months) | Survival analysis | HR estimate | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yoshikawa (2018) [20] | Japan | 341 | 16–82 (53 median) | 95 (28%) | NR | NR | S144, M60, E52, C85 | 166/175 | NR | NR | RmAb | NR | > 10% | median 58 (1–257) | OS/PFS | HR | 8 |
Yang [21] (2013) | USA | 49 | 41–87 (61 median) | 25 (51.02%) | NR | NR | SME47, CU2 | 16/33 | 18/31 | NR | Ab | E | ≥50% | NR | OS | HR | 7 |
Min [22] (2009) | China | 50 | 22–73 (50.6 median) | 29 (58%) | 44 (88%) | 50/NR/20/20 | S45, M2, C2, O1 | 18/32 | 34/16 | 9/22 | Ab | I,E(P) | 1+, ≥10%(P) | NR | OS | K-M | 7 |
Shang [23] (2017) | China | 136 | 21–83 (54 median) | 72 (52.94%) | 86 (63.23%) | NR | S72, M36, E15, C13 | 56/80 | 52/84 | 59/77 | R Ab | EI | ≥4 | 48 | OS | HR | 8 |
Rosen [24] (2006) | USA | 303 | 20–86 (58.2 median) | 261 (86%) | NR | NR | S232, M6, E33, C15, O36 | 56/247 | 14/289 | NR | Ab | EI | ≥3 | median 64 (1–120) | OS | K-M | 8 |
Xiao [25] (2015) | China | 40 | NR | 32 (80%) | NR | 40/20/20/NR | NR | NR | 12/28 | 31/9 | Ab | EI | ≥3 | NR | NR | NR | 5 |
Gao [26] (2013) | China | 34 | 30–78 (55.6 median) | NR | 28 (82.4%) | 34/10/10/NR | S18, M10, E4, C2 | 12/22 | 19/15 | 20/14 | RmAb | E | ≥6% | NR | NR | NR | 5 |
Wu [27] (2021) | China | 130 | 23–67 (53 median) | NR | 90 (69.2%) | 130/30/20/NR | NR | 47/83 | NR | 52/78 | MAb | EI | > 1+ ≥25% | NR | NR | NR | 8 |
Zhang [28] (2008) | China | 56 | 34–71 (52.5 median) | NR | 49 (87.5%) | 56/18/35/25 | NR | 12/44 | 35/21 | 32/24 | RpAb | EI | ≥2 | NR | NR | NR | 6 |
Chen [29] (2017) | China | 31 | NR | 10 (32.26%) | NR | NR | S15, M4, E7, C5 | 10/21 | NR | NR | Ab | EI | ≥3 | NR | NR | NR | 8 |
Li [30] (2020) | China | 156 | 23–73 (50.6 median) | 86 (55.13%) | NR | NR | S116, M22, E12, O6 | 46/110 | 64/84 | 43/113 | Ab | E | ≥50% | median 84 (60–108) | OS/PFS | K-M | 7 |
Yanaihara [31] (2016) | Japan | 84 | NR | 33 (39.29%) | NR | NR | NR | 63/21 | NR | NR | Ab | EI | > 2 | NR | OS/PFS | HR | 8 |
Wouters [32] (2015) | Netherland | 101 | 57.99 median | 20 (20%) | NR | NR | S57, M7, E18 | 27/74 | NR | NR | RmAb | EI | ≥3 | NR | NR | NR | 8 |
Chaluvally_Raghavan [33] (2016) | USA | 145 | 35–88 (58.8 median) | NR | 67 (46.2%) | NR | S145 | 9/136 | NR/145 | NR | Ab | EI | > 1 | NR | OS | K-M | 7 |
Guan [34] (2010) | China | 42 | 37–72 (52 median) | NR | 34 (80.95%) | 42/NR/25/13 | S29, M9, E4 | 9/33 | NR | NR | RAb | EI | ≥3 | NR | NR | NR | 6 |
Hong [35] (2017) | China | 49 | 42–76 (63.4 median) | NR | 34 (69.4%) | 49/NR/14/NR | NR | 35/14 | NR | NR | Ab | EI | ≥3 | NR | NR | NR | 5 |